# Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

> **NCT03535961** · PHASE2 · COMPLETED · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 32 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** apatinib+oral etoposide

## Key facts

- **NCT ID:** NCT03535961
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2019-05-01
- **Final completion:** 2019-05-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535961, "Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03535961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*